When we restricted our analyses to breast cancer tumors that were either estrogen-receptor or progesterone-receptor positive (ER+/PR+), the overall pattern of estimated risks was generally similar to those observed for all tumor types considered in our original analysis (data not shown). The gene discussed is ESR1; the disease is breast carcinoma.